RXRX Stock Price, Recursion Pharmaceuticals, . Quote, Chart

Market Summary

USD9.42-0.09

Delayed

-0.95%

RXRX Alerts

2 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

RXRX Stock Price

View Fullscreen

RXRX RSI Chart

RXRX Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-6.32

Price/Sales (Trailing)

48.39

EV/EBITDA

-6.35

Price/Free Cashflow

-6.78

RXRX Price/Sales (Trailing)

RXRX Profitability

EBT Margin

-718.35%

Return on Equity

-88.27%

Return on Assets

-63.48%

Free Cashflow Yield

-14.76%

RXRX Fundamentals

RXRX Revenue

Revenue (TTM)

46.2M

Rev. Growth (Yr)

13.68%

Rev. Growth (Qtr)

26.66%

RXRX Earnings

Earnings (TTM)

-354.1M

Earnings Growth (Yr)

-39.87%

Earnings Growth (Qtr)

1.75%

Breaking Down RXRX Revenue

Last 7 days

9.5%

Last 30 days

26.1%

Last 90 days

-28.4%

Trailing 12 Months

72.2%

How does RXRX drawdown profile look like?

RXRX Financial Health

Current Ratio

4.65

RXRX Investor Care

Shares Dilution (1Y)

23.55%

Diluted EPS (TTM)

-1.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	46.2M	0	0	0
2023	46.6M	50.0M	47.4M	44.6M
2022	12.9M	18.1M	28.7M	39.8M
2021	25.2M	8.8M	10.3M	10.2M
2020	2.7M	3.1M	3.6M	4.0M
2019	0	0	0	2.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Recursion Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	gibson christopher	acquired	-	-	21,296	chief executive officer
May 02, 2024	gibson christopher	sold	-423,500	8.47	-50,000	chief executive officer
May 01, 2024	gibson christopher	sold	-386,500	7.73	-50,000	chief executive officer
May 01, 2024	gibson christopher	gifted	-	-	-25,000	chief executive officer
Apr 30, 2024	borgeson blake	sold	-90,963	7.9465	-11,447	-
Apr 25, 2024	marriott tina	sold	-23,020	7.6735	-3,000	president and coo
Apr 25, 2024	marriott tina	acquired	3,180	1.06	3,000	president and coo
Apr 17, 2024	secora michael	acquired	83,250	2.22	37,500	chief financial officer
Apr 17, 2024	secora michael	sold	-175,349	7.583	-23,124	chief financial officer
Apr 16, 2024	secora michael	acquired	83,250	2.22	37,500	chief financial officer

Which funds bought or sold RXRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-38.15	-1,265,500	2,113,140	-%
May 16, 2024	Ancora Advisors LLC	unchanged	-	2.00	229	-%
May 16, 2024	COMERICA BANK	added	26.36	7,770	35,753	-%
May 16, 2024	Oxford Wealth Group, LLC	new	-	106,081	106,081	0.10%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	3.23	64,598	1,540,280	-%
May 16, 2024	Mubadala Investment Co PJSC	unchanged	-	1,428,450	129,470,000	0.51%
May 15, 2024	Cubist Systematic Strategies, LLC	added	135	179,067	308,272	-%
May 15, 2024	CITADEL ADVISORS LLC	added	832	3,033,700	3,393,530	-%
May 15, 2024	Laurion Capital Management LP	unchanged	-	99,838	9,048,930	0.08%
May 15, 2024	Engineers Gate Manager LP	added	411	467,747	579,865	0.01%

Are Funds Buying or Selling RXRX?

Are funds buying RXRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RXRX

No. of Funds

Unveiling Recursion Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.52%	15,665,210	SC 13G/A
Feb 12, 2024	ark investment management llc	11.08%	23,076,052	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 29, 2024	blackrock inc.	6.0%	12,393,872	SC 13G/A
Jan 29, 2024	ark investment management llc	9.92%	20,654,287	SC 13G
Jan 26, 2024	baillie gifford & co	11.61%	24,179,504	SC 13G/A
Jan 24, 2024	state street corp	5.83%	12,151,646	SC 13G
May 22, 2023	kinnevik ab (publ)	5.6%	10,405,668	SC 13G
Feb 14, 2023	lux capital management, llc	3.3%	6,004,722	SC 13G/A
Feb 09, 2023	vanguard group inc	5.54%	10,057,363	SC 13G

Recent SEC filings of Recursion Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 14, 2024	144	Notice of Insider Sale Intent
May 10, 2024	S-8	Employee Benefits Plan
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 03, 2024	4	Insider Trading

Peers (Alternatives to Recursion Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Recursion Pharmaceuticals, Inc. News

Latest updates

Recursion Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	26.7%	13,794,000	10,891,000	10,533,000	11,017,000	12,134,000	13,676,000	13,160,000	7,674,000	5,333,000	2,533,000	2,534,000	2,549,000	2,562,000	2,691,000	1,025,000	18,943,000	-	-
Costs and Expenses	0.3%	110,134,000	109,821,000	110,083,000	92,732,000	81,999,000	74,658,000	75,733,000	73,865,000	61,314,000	67,493,000	48,936,000	43,478,000	33,046,000	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	67,493,000	48,936,000	43,478,000	33,046,000	28,272,000	23,499,000	18,403,000	18,403,000	-
S&GA Expenses	-100.0%	-	30,458,500	29,199,000	28,290,000	22,874,000	19,838,000	19,488,000	21,199,000	21,074,000	19,201,000	15,690,000	13,854,000	8,937,000	7,574,000	6,964,000	5,159,000	5,561,000	-
R&D Expenses	-2.8%	67,560,000	69,482,000	70,007,000	55,060,000	46,677,000	43,980,000	40,836,000	38,439,000	32,441,000	48,292,000	33,246,000	29,624,000	24,109,000	20,698,000	16,535,000	13,244,000	12,842,000	-
EBITDA Margin	4.7%	-6.57	-6.90	-4.63	-4.48	-4.86	-5.71	-6.12	-9.74	-13.61	-17.43	-	-	-	-	-	-	-	-
Interest Expenses	-100.0%	-	60,000	11,000	12,000	13,000	13,000	14,000	14,000	14,000	15,000	125,000	286,000	254,000	166,000	101,000	416,000	306,000	-
Income Taxes	-Infinity%	-779,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-Infinity%	-92,152,000	-	-	-	-65,327,000	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	3.6%	-7.18	-7.45	-5.06	-4.79	-5.13	-6.01	-6.50	-10.32	-14.40	-18.32	-	-	-	-	-	-	-	-
Net Income	1.7%	-91,373,000	-92,996,000	-93,017,000	-76,726,000	-65,327,000	-57,492,000	-60,445,000	-65,560,000	-55,979,000	-64,933,000	-47,428,000	-43,401,000	-30,717,000	-25,766,000	-23,873,000	-18,943,000	-18,424,000	-
Net Income Margin	-4.1%	-7.66	-7.36	-6.18	-5.20	-5.33	-6.01	-8.60	-12.94	-16.35	-18.32	-14.25	-14.02	-3.94	-21.96	-17.42	-19.70	-22.67	-26.68
Free Cashflow	-43.1%	-108,953,000	-76,144,000	-73,665,000	-71,435,000	-78,491,000	-52,727,000	-62,804,000	-78,098,000	73,046,000	-65,622,000	-42,754,000	-39,865,000	-50,171,000	4,886,000	-20,282,000	-17,333,000	-18,501,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-14.7%	558	654	631	667	627	701	612	673	734	610	659	699	272	299
Current Assets	-21.6%	344	438	411	431	492	570	482	546	619	535	601	648	222	266
Cash Equivalents	-21.8%	306	392	387	406	473	550	465	464	518	295	405	643	219	267
Net PPE	0.2%	87.00	87.00	86.00	90.00	90.00	88.00	86.00	82.00	71.00	65.00	55.00	49.00	45.00	26.00
Goodwill	0%	52.00	52.00	53.00	61.00	1.00	1.00	1.00	1.00	1.00	1.00	-	-	-	1.00
Liabilities	-17.6%	157	190	193	198	197	215	223	235	241	67.00	60.00	56.00	57.00	57.00
Current Liabilities	-20.7%	74.00	93.00	94.00	114	92.00	100	83.00	97.00	86.00	47.00	43.00	30.00	27.00	23.00
Shareholder's Equity	-13.4%	401	463	438	469	430	486	388	438	494	543	599	643	-	-
Retained Earnings	-13.7%	-1,100	-967	-874	-781	-704	-639	-582	-521	-456	-400	-335	-287	-244	-213
Additional Paid-In Capital	2.0%	1,460	1,431	1,313	1,251	1,135	1,125	970	959	950	943	934	930	11.00	7.00
Shares Outstanding	1.4%	238	234	216	207	192	191	172	171	171	125	111	81.00	23.00	22.00
Float	-	-	-	-	930	-	-	-	941	-	-	-	3,900	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-38.1%	-102,300	-74,077	-72,920	-67,467	-73,316	-44,748	-54,541	-61,623	77,388	-61,158	-33,048	-33,653	-30,755	8,573	-19,456	-16,699	-17,817	-
Share Based Compensation	0.3%	16,127	16,086	16,792	11,811	8,814	7,695	8,907	5,675	5,632	4,341	3,363	5,317	1,821	1,188	1,070	769	1,265	-
Cashflow From Investing	-167.4%	-6,653	-2,488	-347	-2,053	-5,340	-7,979	52,984	4,940	143,304	-52,243	-193,873	-6,212	-19,416	-4,591	-3,426	-39.00	-684	-
Cashflow From Financing	-82.8%	13,897	80,659	53,765	3,787	1,922	147,256	2,337	2,668	2,084	3,796	-11,095	463,705	2,134	10,035	229,721	382	5,997	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RXRX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue
Total revenue	$ 13,794	$ 12,134
Operating costs and expenses
Cost of revenue	11,166	12,448
Research and development	67,560	46,677
General and administrative	31,408	22,874
Total operating costs and expenses	110,134	81,999
Loss from operations	(96,340)	(69,865)
Other income, net	4,188	4,538
Loss before income tax benefit	(92,152)	(65,327)
Income tax benefit	779	0
Net loss and comprehensive loss	(91,373)	(65,327)
Net loss and comprehensive loss	$ (91,373)	$ (65,327)
Per share data
Net loss per share of Class A, B and Exchangeable common stock, basic (in dollars per share)	$ (0.39)	$ (0.34)
Net loss per share of Class A, B and Exchangeable common stock, diluted (in dollars per share)	$ (0.39)	$ (0.34)
Weighted-average shares (Class A, B and Exchangeable) outstanding, basic (in shares)	236,019,349	191,618,238
Weighted-average shares (Class A, B and Exchangeable) outstanding, diluted (in shares)	236,019,349	191,618,238
Operating revenue
Revenue
Total revenue	$ 13,491	$ 12,134
Grant revenue
Revenue
Total revenue	$ 303	$ 0

RXRX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 296,326	$ 391,565
Restricted cash	3,195	3,231
Other receivables	2,599	3,094
Other current assets	41,495	40,247
Total current assets	343,615	438,137
Restricted cash, non-current	6,629	6,629
Property and equipment, net	86,716	86,510
Operating lease right-of-use assets	35,501	33,663
Intangible assets, net	33,076	36,443
Goodwill	52,056	52,056
Other assets, non-current	254	261
Total assets	557,847	653,699
Current liabilities
Accounts payable	5,115	3,953
Accrued expenses and other liabilities	26,070	46,635
Unearned revenue	36,618	36,426
Notes payable	55	41
Operating lease liabilities	6,062	6,116
Total current liabilities	73,920	93,171
Unearned revenue, non-current	37,391	51,238
Notes payable, non-current	1,071	1,101
Operating lease liabilities, non-current	43,786	43,414
Deferred tax liabilities	528	1,339
Total liabilities	156,696	190,263
Commitments and contingencies (Note 7)
Stockholders’ equity
Common stock, $0.00001 par value; 2,000,000,000 shares (Class A 1,989,032,117 and Class B 10,967,883) authorized as of March 31, 2024 and December 31, 2023; 237,508,682 shares (Class A 230,043,061, Class B 7,464,871 and Exchangeable 750) and 234,270,384 shares (Class A 226,264,764, Class B 7,544,871 and Exchangeable 460,749) issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2	2
Additional paid-in capital	1,460,144	1,431,056
Accumulated deficit	(1,058,995)	(967,622)
Total stockholders’ equity	401,151	463,436
Total liabilities and stockholders’ equity	$ 557,847	$ 653,699

About Recursion Pharmaceuticals, Inc.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CEO	Dr. Christopher C. Gibson Ph.D.
WEBSITE	recursion.com
INDUSTRY	Biotechnology
EMPLOYEES	550

Recursion Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Recursion Pharmaceuticals, Inc.? What does RXRX stand for in stocks?

RXRX is the stock ticker symbol of Recursion Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Recursion Pharmaceuticals, Inc. (RXRX)?

As of Fri May 17 2024, market cap of Recursion Pharmaceuticals, Inc. is 2.24 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RXRX stock?

You can check RXRX's fair value in chart for subscribers.

What is the fair value of RXRX stock?

You can check RXRX's fair value in chart for subscribers. The fair value of Recursion Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Recursion Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RXRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Recursion Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether RXRX is over valued or under valued. Whether Recursion Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Recursion Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RXRX.

What is Recursion Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RXRX's PE ratio (Price to Earnings) is -6.32 and Price to Sales (PS) ratio is 48.39. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RXRX PE ratio will change depending on the future growth rate expectations of investors.